Pilot study [Power / Sample Size]

posted by konkous – Greece, 2020-12-11 08:25 (528 d 10:30 ago) – Posting: # 22140
Views: 1,377

Dear colleagues,

We have conducted an in-vitro permeation pilot study for confirming the suitability of our design in terms of time points, duration and for estimating the sample size for the pivotal study based on the within-reference %CV and the GMR calculated. The GMR was approximately 1.19 and the %CV around 25%. As it can easily be inferred the 90% C.I did not fall within the 0.80-1.25 interval. I realize that no safe conclusions can be drawn from a very small sample size regarding the equivalence of the products but i wonder if there is an established methodology for assessing if there is any point in proceeding with the pivotal study.

Thank you,

Best regards,

Constantinos


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,092 posts in 4,630 threads, 1,567 registered users;
online 14 (0 registered, 14 guests [including 6 identified bots]).
Forum time: Monday 19:55 CEST (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5